Advanced search×

Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells.

Cancer Chemother Pharmacol 68(5):1161-72 (2011) PMID 21400027

Doxorubicin is a first-line chemotherapeutic for breast cancer; however, it is associated with severe side effects to non-tumoral tissues. Thus, it is necessary to develop new therapeutic combinations to improve doxorubicin effects at lower concentration of the drug associated with protective effects for non-tumoral cells. In this work, we evaluated whether the plant-derived flavonoid quercetin may represent such an agent.

DOI: 10.1007/s00280-011-1596-x
Version: za2963e q8za0 q8zb8 q8zc8 q8zd2 q8ze7 q8zf8 q8zg4

Similar articles you may find interesting…

  1. Human Cytochromes P450: Evolution and cDNA-Directed Expression

    Environ Health Perspect (1992) PMID 1486867

    As the first step in the process of carcinogenesis, most chemical carcinogens require metabolic activation by cytochromes P450 for conversion to highly reactive electrophiles that bind covalently to DNA. Studies in rodents suggest that low or high levels of expression of a single P450 can determine...
  2. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-ass...

    Cancer Res 59(15):3663-70 (1999) PMID 10446979

    We have shown that the transcriptional status of p53 determines the sensitivity to antimicrotubule drugs and that this is mediated through the regulation of microtubule-associated protein 4 (MAP4). Expression of MAP4 is transcriptionally repressed by wild-type p53. Increased expression of MAP4, whic...
  3. 'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass.

    Osteoporos Int 23(2):643-54 (2012) PMID 21455762

    Individuals with unexplained HBM had an excess of sinking when swimming (7.11 [3.65, 13.84], p < 0.001), extra bone at tendon/ligament insertions (2.07 [1.13, 3.78], p = 0.018) an...